Tandem Diabetes Care, Inc. (TNDM) Receives “Outperform” Rating from Wedbush

Wedbush reissued their outperform rating on shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in a report published on Tuesday morning. Wedbush currently has a $17.00 price objective on the medical device company’s stock, down from their previous price objective of $50.00.

TNDM has been the subject of a number of other research reports. Piper Jaffray Companies restated a hold rating and issued a $15.00 price objective on shares of Tandem Diabetes Care in a research note on Friday, October 6th. Zacks Investment Research upgraded Tandem Diabetes Care from a hold rating to a buy rating and set a $7.50 price target for the company in a research note on Thursday, September 28th. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Tandem Diabetes Care currently has an average rating of Buy and a consensus target price of $29.31.

Shares of Tandem Diabetes Care (TNDM) traded up 1.23% during midday trading on Tuesday, reaching $5.37. The company’s stock had a trading volume of 51,234 shares. Tandem Diabetes Care has a one year low of $3.90 and a one year high of $77.70. The firm has a 50-day moving average of $6.81 and a 200-day moving average of $7.89. The stock’s market cap is $269.72 million.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, July 27th. The medical device company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.80) by $0.40. The firm had revenue of $21.30 million during the quarter, compared to the consensus estimate of $21.74 million. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 110.70%. The business’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($6.00) EPS. On average, analysts forecast that Tandem Diabetes Care will post ($1.79) EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://ledgergazette.com/2017/10/11/tandem-diabetes-care-inc-tndm-receives-outperform-rating-from-wedbush.html.

Several hedge funds have recently bought and sold shares of the company. Iguana Healthcare Management LLC grew its stake in shares of Tandem Diabetes Care by 33.3% during the 1st quarter. Iguana Healthcare Management LLC now owns 100,000 shares of the medical device company’s stock worth $120,000 after acquiring an additional 25,000 shares during the period. Vanguard Group Inc. grew its stake in shares of Tandem Diabetes Care by 2.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock worth $987,000 after acquiring an additional 32,991 shares during the period. Keybank National Association OH grew its stake in shares of Tandem Diabetes Care by 32.7% during the 2nd quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock worth $235,000 after acquiring an additional 72,177 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Tandem Diabetes Care by 93.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 581,245 shares of the medical device company’s stock worth $465,000 after acquiring an additional 280,551 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of Tandem Diabetes Care by 88.6% during the 1st quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock worth $1,032,000 after acquiring an additional 404,452 shares during the period. Institutional investors own 36.64% of the company’s stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for peo

TNDM has been the subject of a number of other research reports. Piper Jaffray Companies restated a hold rating and issued a $15.00 price objective on shares of Tandem Diabetes Care in a research note on Friday, October 6th. Zacks Investment Research upgraded Tandem Diabetes Care from a hold rating to a buy rating and set a $7.50 price target for the company in a research note on Thursday, September 28th. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Tandem Diabetes Care currently has an average rating of Buy and a consensus target price of $29.31.

Shares of Tandem Diabetes Care (TNDM) traded up 1.23% during midday trading on Tuesday, reaching $5.37. The company’s stock had a trading volume of 51,234 shares. Tandem Diabetes Care has a one year low of $3.90 and a one year high of $77.70. The firm has a 50-day moving average of $6.81 and a 200-day moving average of $7.89. The stock’s market cap is $269.72 million.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, July 27th. The medical device company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.80) by $0.40. The firm had revenue of $21.30 million during the quarter, compared to the consensus estimate of $21.74 million. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 110.70%. The business’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($6.00) EPS. On average, analysts forecast that Tandem Diabetes Care will post ($1.79) EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://ledgergazette.com/2017/10/11/tandem-diabetes-care-inc-tndm-receives-outperform-rating-from-wedbush.html.

Several hedge funds have recently bought and sold shares of the company. Iguana Healthcare Management LLC grew its stake in shares of Tandem Diabetes Care by 33.3% during the 1st quarter. Iguana Healthcare Management LLC now owns 100,000 shares of the medical device company’s stock worth $120,000 after acquiring an additional 25,000 shares during the period. Vanguard Group Inc. grew its stake in shares of Tandem Diabetes Care by 2.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock worth $987,000 after acquiring an additional 32,991 shares during the period. Keybank National Association OH grew its stake in shares of Tandem Diabetes Care by 32.7% during the 2nd quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock worth $235,000 after acquiring an additional 72,177 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Tandem Diabetes Care by 93.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 581,245 shares of the medical device company’s stock worth $465,000 after acquiring an additional 280,551 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of Tandem Diabetes Care by 88.6% during the 1st quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock worth $1,032,000 after acquiring an additional 404,452 shares during the period. Institutional investors own 36.64% of the company’s stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply